Cite
HARVARD Citation
Pishvaian, M. et al. (2018). A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 124 (11), pp. 2337-2346. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pishvaian, M. et al. (2018). A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 124 (11), pp. 2337-2346. [Online].